GlassScriptPhysician profile
Howard Elliot Katzman
NPI 1306849724
$3,478.31
in general payments reported to CMS, 2019-2025
34 companies · $493 in 2025
The $493 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $843 · 2021: $282 · 2022: $847 · 2023: $342 · 2024: $425 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $572.05 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $466.08 | 2019-2024 | Venclose Maven Catheter |
| W. L. Gore & Associates, INC. | $451.81 | 2020-2022 | |
| Smith+Nephew, INC. | $351.47 | 2020-2025 | Grafix Pl, Stravix, Oasis |
| Stryker Corporation | $218.72 | 2025 | Limflow System, Inthrill Thrombectomy Catheter |
| Janssen Pharmaceuticals, INC | $141.27 | 2019-2022 | |
| Axogen | $117.73 | 2023-2024 | Avance Nerve Graft, Axoguard Nerve Protector, Axoguard Nerve Cap |
| Dilon Technologies, INC. | $107.83 | 2023-2024 | Hemoblast Bellows |
| Baxter Healthcare | $96.22 | 2019-2025 | |
| Penumbra, INC. | $81.13 | 2024-2025 | Penumbra System, Indigo System |
| Organogenesis INC. | $76.84 | 2021-2025 | Puraply Wound Matrix, Puraply |
| Biom'Up France Sas | $72.76 | 2020 | |
| Medtronic Vascular, INC. | $66.67 | 2019 | |
| Medtronic, INC. | $64.36 | 2023 | Closurefast, Venaseal |
| Osprey Medical INC | $50.64 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $46.63 | 2019-2022 | |
| Angiodynamics, INC. | $39.99 | 2021 | |
| Kerecis Limited | $39.71 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Humacyte Global, INC. | $39.22 | 2025 | Symvess |
| Pfizer INC. | $38.63 | 2021-2022 | |
| Biotissue Holdings INC. | $35.02 | 2023 | |
| Kci USA, INC. | $34.32 | 2022-2023 | Kerramax Care, Activ.A.C., 3m Coban |
| Biocompatibles, INC. | $32.39 | 2019 | |
| Neuros Medical, INC. | $32.23 | 2025 | Altius |
| Cormedix INC. | $27.90 | 2024 | Defencath |
| Acera Surgical, INC. | $22.71 | 2022 | |
| Cook Medical LLC | $21.27 | 2022 | |
| Silk Road Medical, INC. | $21.22 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Shockwave Medical, INC | $20.96 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Solventum Corporation | $20.33 | 2024 | V.A.C. Veraflo, Prevena |
| Boston Scientific Corporation | $18.45 | 2024 | |
| Tactile Systems Technology INC | $18.05 | 2022 | |
| Convatec INC. | $17.32 | 2023 | |
| Argon Medical Devices, INC. | $16.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Katzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.